Report Code: A15411 | Pages: NA | Mar 2023 | 769 Views | ||
Author(s) : NA | Tables: NA | Charts: NA |
|
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Her2-positive Breast Cancer Market
Request Now !Human epidermal growth factor receptor 2 (HER2) is a gene that is linked to breast cancer development. Genes contain the recipes for numerous proteins required by a cell to remain healthy and function normally. This protein stimulates cancer cell proliferation. Cancer cells in around one out of every five breast tumors have extra copies of the gene that produces the HER2 protein. Breast cancers that are HER2-positive are more aggressive than other kinds of breast cancer. Although anticancer medications do not directly target the HER2 protein, certain regular chemotherapy treatments can be useful in treating HER2-positive breast tumors. Experts advise testing for the presence of HER2 in all invasive breast cancers since the results have a substantial impact on treatment recommendations and decisions. Except as part of a clinical trial, HER2 testing is not typically performed for ductal carcinoma in situ. When breast cancer recurs or expands, the cancer cells should be retested for HER2 and hormone receptor status, as these can alter after the original diagnosis.
COVID-19 Impact Analysis:
Pharmaceutical and biotech companies together with governments globally are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, about 115 vaccine samples and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the rise in the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the HER2-positive breast cancer market.Â
Top Impacting Factors:
Market Trends:
New Product Launches to Flourish HER2-Positive Breast Cancer Market
In May 2019, the Food and Drug Administration (FDA) approved ado-trastuzumab emtansine (KADCYLA, Genentech, Inc.) for the adjuvant treatment of patients with HER2-positive early breast cancer (EBC) who have the residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.
Key Benefits of Report:
Questions Answered in the HER2-Positive Breast Cancer Market Report:
HER2-Positive Breast Cancer Market Report Highlights
Aspects | Details |
---|---|
By Treatment Type |
|
By Route of Administration |
|
By End User |
|
By Distribution Channel |
|
By Region |
|
Key Market Players | Pfizer Inc., Eli Lilly and Company, AstraZeneca, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bayer AG, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Novartis AG, Teva Pharmaceuticals Industries Ltd., Baxter, Mylan N.V., Fresenius Kabi AG |
Loading Table Of Content...
Start reading.
This Report and over 19,609+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers